Hussman Strategic Advisors Inc. Acquires Shares of 31,500 Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Hussman Strategic Advisors Inc. purchased a new position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 31,500 shares of the company's stock, valued at approximately $913,000. Hussman Strategic Advisors Inc. owned approximately 0.07% of Amphastar Pharmaceuticals at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of AMPH. Tower Research Capital LLC TRC boosted its position in shares of Amphastar Pharmaceuticals by 43.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company's stock valued at $43,000 after buying an additional 348 shares during the last quarter. Huntington National Bank lifted its stake in Amphastar Pharmaceuticals by 36.9% during the 4th quarter. Huntington National Bank now owns 1,340 shares of the company's stock valued at $50,000 after acquiring an additional 361 shares during the period. Bank of Montreal Can boosted its holdings in shares of Amphastar Pharmaceuticals by 4.6% during the 4th quarter. Bank of Montreal Can now owns 8,215 shares of the company's stock valued at $305,000 after acquiring an additional 361 shares during the last quarter. TD Private Client Wealth LLC grew its stake in shares of Amphastar Pharmaceuticals by 22.7% in the fourth quarter. TD Private Client Wealth LLC now owns 2,099 shares of the company's stock worth $78,000 after acquiring an additional 388 shares during the period. Finally, GAMMA Investing LLC raised its holdings in shares of Amphastar Pharmaceuticals by 46.6% during the first quarter. GAMMA Investing LLC now owns 1,333 shares of the company's stock valued at $39,000 after purchasing an additional 424 shares during the last quarter. 65.09% of the stock is owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Price Performance

Shares of NASDAQ AMPH traded up $0.16 during midday trading on Tuesday, reaching $21.35. 469,496 shares of the stock traded hands, compared to its average volume of 500,931. The company's 50 day moving average is $24.16 and its 200 day moving average is $27.56. Amphastar Pharmaceuticals, Inc. has a one year low of $20.43 and a one year high of $53.96. The company has a debt-to-equity ratio of 0.80, a current ratio of 2.95 and a quick ratio of 2.02. The stock has a market capitalization of $1.01 billion, a PE ratio of 7.74 and a beta of 0.72.

Analysts Set New Price Targets

AMPH has been the subject of a number of research analyst reports. JPMorgan Chase & Co. reaffirmed a "neutral" rating and issued a $30.00 target price (down previously from $45.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, May 12th. Needham & Company LLC restated a "hold" rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, April 10th. Finally, Wells Fargo & Company lowered their price objective on shares of Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating on the stock in a research note on Thursday, May 8th. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $32.33.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.